34
Participants
Start Date
October 31, 2025
Primary Completion Date
July 31, 2028
Study Completion Date
January 31, 2029
Somatropin (recombinant human growth hormone)
Study participants will deliver Somatropin via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks at a dose of 0.5mg/day per body surface area (0.5mg/m2/day).
bacteriostatic saline placebo
Study participants will deliver bacteriostatic saline via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks in an identical delivery device to the experimental arm.
Sunnybrook Health Sciences Centre, Toronto
Sunnybrook Research Institute
OTHER
Dr. David Wasserstein
OTHER